Compare MobilEye Global Inc (MBLY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Medpace Holdings Inc — how do they compare? MobilEye Global Inc trades at $7.12 (market cap $6.00B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.8× MobilEye Global Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Medpace Holdings Inc for 14 Days on average.
| MBLY | MEDP | |
|---|---|---|
Market Cap | $6.00B | $16.82B |
Volume | 7,007,849 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $630.19 |
52-Week Low | $6.56 | $393.42 |
Typical Hold Time | 15 Days | 14 Days |
Enterprise Value | $4.56B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.11, down 0.56% on the day, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -201.49% for 2026, yet revenue grew to $2.0 billion. Recent earnings beats in Q1 and Q2 2026 contrast with a Q4 2025 miss, while analyst consensus is a 'Buy' with a $10.83 price target. News highlights ADAS momentum and a robotaxi strategy expansion, but the stock faces significant cash flow volatility.
The outlook for MBLY is cautious; while analyst optimism and revenue growth provide upside potential, persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of autonomous driving programs, but shareholders face volatility from negative earnings and high valuation multiples like EV/EBITDA of 32.34.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
